BioSpace News Archive

ReCor Medical, Inc. (“ReCor”) and its parent company, Otsuka Medical Devices Co., Ltd. (“Otsuka Medical Devices”) today announced that primary endpoint results from the RADIANCE II pivotal trial were published in the Journal of the American Medical Association (JAMA).

DiscGenics, Inc. today announced that it will present at Canaccord Genuity’s 18th Annual Musculoskeletal Conference taking place in Las Vegas, NV on Tuesday, March 7, 2023.

Ascelia Pharma AB (publ) (ticker: ACE), a biotech focused on improving the life of people living with rare cancer conditions, today announced the successful completion of patient enrollment in the company’s pivotal phase 3 clinical study, SPARKLE, with the lead candidate drug Orviglance®.

Sparta Biomedical, a privately held medical device company specializing in partial knee resurfacing, is set to present at the highly anticipated Canaccord Genuity Musculoskeletal Conference on Tuesday, March 7, 2023.

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that Emil D. Kakkis, M.D., Ph.D., the company’s chief executive officer and president, will participate in an Orphan Neuro Panel at Cowen’s 43rd Annual Health Care Conference on Tuesday, March 7, 2023, at 10:30 a.m. ET.

Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today provided a corporate update and reported financial results for the quarter and year ended December 31, 2022.

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Bolyn Hubby, Ph.D., Executive Vice President and Chief Corporate Affairs Officer, will participate in a panel focused on infectious diseases at the Cowen 43rd Annual Health Care Conference on Tuesday, March 7, at 6:10 a.m. PT / 9:10 a.m. ET.

Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported financial results for the fourth quarter and year ended December 31, 2022 and provided a corporate update.

Eyenovia, Inc. announced that Stephen Benjamin, an independent director on the Company’s Board of Directors, is stepping down to assume the role of Head of the White House’s Office of Public Engagement.

Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD) through Phase 2 clinical trials, announced today that the last subjects have been enrolled and randomized in the Company’s OraGrowtH210 and OraGrowtH212 trials evaluating LUM-201 for the treatment of moderate idiopathic PGHD.